Back to research
    Deep Dive

    Quad Agonists Explained: CT-G32, NA-931 and Four Receptors

    November 20268 min readBy the Peptx research team

    Quad agonists are single molecules that act on four receptors. What CT-G32 (SCO-940), NA-931 and VRX-0075 are, what the animal and early human data show as of November 2026, and how they differ from retatrutide.

    Quick Answer

    A quad agonist is one molecule that activates four receptors. The clearest example is CT-G32 (SCO-940) from Celltrion and SCOHIA PHARMA, which targets the GLP-1, GIP, glucagon and amylin receptors and has only rat and primate data, first shown in November 2026. NA-931 uses a different four (IGF-1, GLP-1, GIP and glucagon) and has a 28-day phase 1 abstract. As of November 2026 no quad agonist has peer-reviewed human results.

    Key facts

    • Definition: a single molecule with agonist activity at four receptors. Two compounds combined in one vial are not a quad agonist.
    • CT-G32 / SCO-940: GLP-1, GIP, glucagon and amylin receptors. Preclinical. First data presented 3 to 5 November 2026.
    • NA-931: described as acting on IGF-1, GLP-1, GIP and glucagon receptors. Phase 1 abstract (2025); one phase 2 trial listed as completed with no results posted.
    • VRX-0075: a five-receptor (quintuple) agonist adding amylin and calcitonin to the retatrutide targets. Rat data only.
    • Peer-reviewed human data on any quad agonist (November 2026): none that we could find.

    Each step in this field has added a receptor: semaglutide acts on one, tirzepatide on two, retatrutide on three. A fourth is the obvious next move. The evidence behind it is much thinner than the term "quad agonist" suggests, and the name covers molecules with different targets.

    What is a quad agonist?

    An agonist is a molecule that switches a receptor on. A quad (or quadruple, or tetra) agonist is a single molecule engineered to switch on four, with one half-life and one fixed balance between its activities.

    The three receptors already combined in retatrutide are closely related. GLP-1, GIP and glucagon are similar hormones acting on similar class B receptors, which is why one peptide can be tuned to fit all three (Coskun et al., 2022). A fourth target usually means a less closely related hormone, so the chemistry gets harder with each addition.

    Which four receptors does CT-G32 target?

    CT-G32, called SCO-940 by its Japanese co-developer, is designed to act on the GLP-1, GIP, glucagon and amylin receptors. That is the three retatrutide targets plus amylin, a fullness hormone released with insulin. SCOHIA PHARMA led discovery and preclinical work under a collaboration begun in 2024; Celltrion leads the later development.

    The first data were presented at TIDES Europe in Amsterdam on 3 to 5 November 2026, according to SCOHIA PHARMA (4 November 2026). As the company reports it:

    • In diet-induced obese rats, CT-G32 produced "numerically greater" weight loss than retatrutide at an equal molar amount.
    • A relatively smaller share of the weight lost was lean body mass.
    • In non-human primates, the compound stayed in the blood for a prolonged period.

    Three cautions apply. This is company-reported animal data from a conference, not a peer-reviewed paper. The release gives no figures: no weight percentages, group sizes or statistics. And "numerically greater" means the number was higher, not that the difference was shown to be statistically reliable.

    On timing, Celltrion said in May 2026 that toxicology studies in rats and monkeys had begun. The November release says Celltrion aims to file an Investigational New Drug application with the US FDA by February 2027 and to start the first human study in the second quarter. As of 16 November 2026, ClinicalTrials.gov lists no study of CT-G32 or SCO-940.

    What is NA-931, and is it the same kind of molecule?

    No. NA-931, from Biomed Industries, is described by its developer as a quadruple agonist of the IGF-1, GLP-1, GIP and glucagon receptors. It has no amylin activity, and its fourth target, the receptor for insulin-like growth factor 1, belongs to a different receptor family from the other three.

    The main public source is an oral presentation at the American Diabetes Association meeting in June 2025 (Tran, 2025, abstract 143-OR). It describes a placebo-controlled phase 1 study in 74 people with overweight or obesity. Over 28 days, mean body weight fell by up to 6.4% from baseline, and the abstract states that no muscle loss was observed.

    This is a short abstract with one listed author. It does not say how muscle was measured, and 28 days is too brief to judge body composition or safety. We found no peer-reviewed paper on NA-931 in PubMed, and no published data showing its activity at each of the four receptors.

    As of 16 November 2026, ClinicalTrials.gov lists three NA-931 studies, all sponsored by Biomed Industries: the phase 1 study (NCT06615700, completed), a phase 2 trial of an oral form in 126 people (NCT06564753, completed in 2025, no results posted on the register), and a phase 2 trial against tirzepatide in 224 people (NCT06732245, not yet recruiting).

    What else is being tried beyond three receptors?

    • VRX-0075 (five receptors). A late-breaking abstract at the American Diabetes Association meeting in June 2026 describes a long-acting quintuple agonist for the GLP-1, GIP, glucagon, amylin and calcitonin receptors. The authors report significantly greater weight loss than retatrutide in obese rats at an equal molar amount (Douros et al., 2026, abstract 2839-LB). Rat data, abstract only.
    • A GLP-1, GIP, glucagon and PYY design. Chemists at Tufts University reported single peptides with high potency at the GLP-1, GIP and glucagon receptors and at Y2R, the receptor for peptide YY (Dinsmore et al., 2025, JACS). This is peer reviewed, but it is a chemistry and receptor-signalling paper. Its abstract reports no animal weight data.
    • A peptide carrying a small molecule. A 2026 Nature paper joined a GLP-1 and GIP receptor agonist to lanifibranor, which acts on three PPAR targets inside cells. In obese mice it lowered body weight, food intake and blood glucose more than the incretin peptide alone or semaglutide (Liskiewicz et al., 2026). Mouse findings.
    CompoundTargetsBest evidence, November 2026
    RetatrutideGIP, GLP-1, glucagonPhase 3 trial, peer reviewed
    CT-G32 / SCO-940GIP, GLP-1, glucagon, amylinRat and primate data, company release
    NA-931IGF-1, GLP-1, GIP, glucagon28-day phase 1, conference abstract
    VRX-0075GIP, GLP-1, glucagon, amylin, calcitoninRat data, conference abstract
    Tufts tetra-agonistsGIP, GLP-1, glucagon, Y2RCell assays, peer reviewed

    How do quad agonists compare with retatrutide?

    Retatrutide is the compound every newer molecule is measured against. Its phase 2 trial reported mean weight reductions of up to 24.2% at 48 weeks (Jastreboff et al., 2023). The phase 3 TRIUMPH-1 trial randomised 2,339 adults with obesity for 80 weeks and reported mean reductions of 17.6% to 25.0% across the retatrutide groups against 3.9% on placebo (Jastreboff et al., 2026). Our retatrutide profile covers the compound in full.

    The comparisons quoted for CT-G32 and VRX-0075 are in rats, and rodent weight loss often fails to carry over to people. A rat result against retatrutide is a reason to run a human study, not a result that ranks the two.

    Why add amylin as the fourth receptor?

    Because the human evidence for pairing amylin with an incretin already exists, using two molecules. In REDEFINE 1, cagrilintide (an amylin analogue) given with semaglutide produced a mean weight change of 20.4% at 68 weeks against 3.0% on placebo in 3,417 adults (Garvey et al., 2025). Eloralintide, a selective amylin receptor agonist, produced reductions of 9% to 20% at 48 weeks in a phase 2 trial of 263 adults (Billings et al., 2025). See our articles on amylin and incretin combinations and eloralintide. CT-G32 and VRX-0075 try to build that activity into the incretin molecule itself.

    Is more receptors automatically better?

    No. Each added receptor brings a trade-off as well as a possible gain.

    • The balance is fixed. In one molecule the ratio between the activities cannot be adjusted afterwards. With separate compounds, each can be studied and varied alone.
    • Glucagon cuts both ways. Glucagon receptor activity raises energy use and acts on liver fat, but glucagon also raises blood glucose. The dual agonists survodutide and mazdutide show how much rests on getting that balance right. The retatrutide phase 2 trial also reported heart rate increases that peaked at 24 weeks.
    • Tolerability adds up. Incretin and amylin agonists both cause nausea in trials. In the eloralintide phase 2 trial, nausea and fatigue were the most common adverse events. Whether four activities in one molecule are tolerated as well as three is untested in people.

    Is Retatrutide plus Eloralintide a quad agonist?

    No. It is two separate molecules, not one. Together they cover the same four receptors as CT-G32: GIP, GLP-1 and glucagon through retatrutide, and amylin through eloralintide. That overlap is why the pairing is sometimes loosely called a "quad agonist" online. The label is inaccurate: each compound keeps its own receptor profile and half-life, and a mixture of two says nothing about how one molecule would behave.

    The pairing is also untested. As of 16 November 2026, ClinicalTrials.gov lists no study combining retatrutide with eloralintide, and we found no published study of the two together. Registered eloralintide combination trials use tirzepatide or macupatide instead.

    Peptx supplies Retalora, a research blend of Retatrutide 10mg and Eloralintide 2.5mg in one lyophilised vial for laboratory use. The amounts are a product specification and are not taken from any trial. For background, see retatrutide and eloralintide combination research and Eloralintide vs Retatrutide.

    The bottom line

    "Quad agonist" describes a design, one molecule and four receptors, and not a proven class. CT-G32 is the clearest example and is still in animal studies, with a first human study planned for 2027. NA-931 uses a different four receptors and has only abstract-level human data. Retatrutide, a triple agonist, has published phase 3 results. Everything beyond it is, as of November 2026, early research.

    References

    1. Billings LK, et al. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. PubMed 41207310
    2. Coskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. PubMed 35985340
    3. Dinsmore TC, et al. (2025). Molecular Design of Unimolecular Tetra-Receptor Agonists. Journal of the American Chemical Society. PubMed 40461942
    4. Douros J, et al. (2026). 2839-LB: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats. Diabetes, 75 (Supplement 1). Conference abstract. doi:10.2337/db26-2839-LB
    5. Garvey WT, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. PubMed 40544433
    6. Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. PubMed 37366315
    7. Jastreboff AM, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. PubMed 42814954
    8. Liskiewicz D, et al. (2026). GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Nature. PubMed 42056522
    9. Tran LL. (2025). 143-OR: NA-931, a Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss. Diabetes, 74 (Supplement 1). Conference abstract. doi:10.2337/db25-143-OR
    10. SCOHIA PHARMA. (4 November 2026). SCOHIA PHARMA Announces Presentation of First Research Results for Quadruple-Agonist Obesity Drug Candidate SCO-940/CT-G32 at TIDES Europe 2026. Company release
    11. Celltrion. (29 May 2026). Celltrion Initiates Primate Toxicology Study for Potential First-in-Class Quadruple-Action Obesity Candidate. Company release
    12. ClinicalTrials.gov. Records for NA-931, eloralintide, retatrutide, CT-G32 and SCO-940, read 16 November 2026. ClinicalTrials.gov search

    Frequently asked questions

    What is a quad agonist?

    A quad agonist, or quadruple agonist, is a single molecule built to activate four different receptors. In obesity research the best-known example is CT-G32 (SCO-940), which targets the GLP-1, GIP, glucagon and amylin receptors. As of November 2026 no quad agonist has published human trial results in a peer-reviewed journal.

    What is CT-G32?

    CT-G32, also called SCO-940, is a preclinical peptide from Celltrion and SCOHIA PHARMA designed to act on the GLP-1, GIP, glucagon and amylin receptors. Its first data, in diet-induced obese rats, were presented at TIDES Europe in Amsterdam on 3 to 5 November 2026. The companies plan a US regulatory filing by February 2027. It has not been tested in people.

    What is NA-931?

    NA-931 is a compound from Biomed Industries described by its developer as a quadruple agonist of the IGF-1, GLP-1, GIP and glucagon receptors. That is a different set of four from CT-G32. Its evidence so far is a conference abstract from a 28-day phase 1 study and company statements. We found no peer-reviewed paper as of November 2026.

    Is a quad agonist better than retatrutide?

    That is not known. The only comparisons are in obese rats, reported by the developers in a press release and a conference abstract. Retatrutide has a published phase 3 trial in 2,339 people. No quad agonist has human data that can be set beside it.

    Is Retatrutide plus Eloralintide a quad agonist?

    No. A quad agonist is one molecule. Retatrutide and eloralintide are two separate molecules that between them act on the GIP, GLP-1, glucagon and amylin receptors. No published or registered study has tested the two together as of November 2026.

    What comes after retatrutide?

    Several directions are in early research: adding amylin to the three retatrutide targets (CT-G32), adding amylin and calcitonin (VRX-0075), adding peptide YY (a Tufts University design), and attaching a small molecule to an incretin peptide (a 2026 Nature paper). All of these are preclinical. None has reached a published human trial.

    Related research

    What net peptide content meansBrowse the research library

    Browse the Peptx catalogue

    Independently tested compounds, typically 99%+ purity (HPLC), factory-direct pricing. UK stock orders placed by 3pm are posted the same day.

    Sold strictly for laboratory research. Not for human consumption.